Scarica l'app Stockscreener
5.62
0.88%
-0.05
Dopo l'orario di chiusura:
5.60
-0.02
-0.36%
Precedente Chiudi:
$5.67
Aprire:
$5.6
Volume 24 ore:
849.46K
Relative Volume:
0.42
Capitalizzazione di mercato:
$558.89M
Reddito:
$98.99M
Utile/perdita netta:
$-197.98M
Rapporto P/E:
-2.8076
EPS:
-2.0017
Flusso di cassa netto:
$-175.32M
1 W Prestazione:
-4.58%
1M Prestazione:
+5.64%
6M Prestazione:
-37.83%
1 anno Prestazione:
-47.43%
Intervallo 1D:
$5.54
$5.70
Intervallo di 1 settimana:
$5.54
$6.09
Portata 52W:
$4.9102
$13.15
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Nome
Ars Pharmaceuticals Inc
Settore
Industria
Telefono
858-771-9307
Indirizzo
11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Compare SPRY vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
5.62 | 547.46M | 98.99M | -197.98M | -175.32M | -2.0017 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-09 | Iniziato | Northland Capital | Outperform |
| 2025-11-04 | Ripresa | Roth Capital | Buy |
| 2025-09-04 | Iniziato | Roth Capital | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-10 | Iniziato | Oppenheimer | Outperform |
| 2024-08-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Reiterato | Leerink Partners | Outperform |
| 2024-07-25 | Iniziato | Raymond James | Outperform |
| 2024-03-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Iniziato | Wedbush | Outperform |
| 2023-01-03 | Iniziato | William Blair | Outperform |
| 2022-12-13 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Ars Pharmaceuticals Inc Borsa (SPRY) Ultime notizie
ARS Pharma (SPRY) Cuts Spending As It Chases Neffy Market Share - Yahoo Finance
SPRY Investors Have Rights – If You Lost Money Investing in - GlobeNewswire
ARS Pharmaceuticals, Inc. (SPRY) LawsuitInvestors Urged to Contact Levi & Korsinsky Before October 5, 2026 - ACCESS Newswire
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
Faruqi & Faruqi, LLP Urges ARS Pharmaceuticals (NASDAQ: SPRY) Inv - The National Law Review
Tejara Capital Ltd Invests $4.86 Million in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesSPRY - YCharts
SPRY Stock Tanks Over 23% After-Hours — ARS Pharmaceuticals Reports No New Major Insurance Wins For Neffy - Stocktwits
ARS Pharmaceuticals (SPRY) insider plans sale after Aug. 18–19 stock disposals - Stock Titan
ARS Pharma (SPRY) Q2 2026 Earnings Call Transcript - AOL.com
ARS Pharmaceuticals (NASDAQ: SPRY) holder plans 25K-share sale after 100K sold - Stock Titan
SPRY Investor Alert: ARS Pharmaceuticals Inc. Securities Class Action NoticeContact SueWallSt - PR Newswire
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 6.3%What's Next? - MarketBeat
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals - GlobeNewswire
Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before the Deadline on October 5, 2026 - The Globe and Mail
SPRY Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in ARS Pharmaceuticals Securities LawsuitContact Levi & Korsinsky - YCharts
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors to ... - Caledonian Record
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages ARS - GlobeNewswire
ARS Pharmaceuticals (NASDAQ: SPRY) holder lines up new 50K-share sale - Stock Titan
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SPRY STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ARS Pharmaceuticals (NASDAQ: SPRY) stockholder plans 49K-share sale - Stock Titan
Richard Lowenthal files to sell up to 50K ARS Pharma (SPRY) shares - Stock Titan
Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Inv - The National Law Review
Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before the Lead Plaintiff Deadline on October 5, 2026 - Barchart.com
SPRY Shareholder Alert: ARS Pharmaceuticals, Inc. Securities Class Action LawsuitInvestors Should Contact The Gross Law Firm - Morningstar
SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmac - The National Law Review
ARS Pharmaceuticals Stock Short Interest Falls to 31.17% - Moomoo
Attention Long-Term Shareholders of ARS Pharmaceuticals, - GlobeNewswire
ARS Pharma Refocuses Strategy As Q2 Revenue Hits $33.7M - RTTNews
ARS Pharma: New CEO's Program Of Reducing Costs While Increasing Revenues Makes A Buy - Seeking Alpha
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
ARS Pharmaceuticals (NASDAQ: SPRY) insider lines up new stock sale - Stock Titan
Robbins LLP Urges SPRY Stockholders Who Lost Money Investing in ARS Pharmaceuticals Inc. to Contact the Firm for Information About Leading the Class Action Lawsuit - PR Newswire
Bragar Eagel & Squire, P.C. Announces that a Class Action - GlobeNewswire
ARS Pharmaceuticals (NASDAQ: SPRY) CCO files first insider report with no shares - Stock Titan
SPRY SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ARS Pharmaceuticals (NASDAQ:SPRY) Trading 5.6% HigherHere's Why - MarketBeat
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm - lincolnjournal.com
SPRY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ARS Pharmace - The National Law Review
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit - The Conway Daily Sun
2026-08-16 | SPRY DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds ARS Pharmaceuticals Inc. Investors to Join the Class Action Lawsuit Today | NDAQ:SPRY | Press Release - Stockhouse
ARS Pharmaceuticals (SPRY) Stock Faces Margin Squeeze As Losses Deepen - Sahm
Analysts Have Lowered Expectations For ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) After Its Latest Results - simplywall.st
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure ... - Caledonian Record
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS - GlobeNewswire
SPRY DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuti - The National Law Review
Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket - Sahm
SPRY Slides As CVS Caremark Delay Triggers Class Action Hit - timothysykes.com
Cantor Fitzgerald Remains a Buy on ARS Pharmaceuticals (SPRY) - The Globe and Mail
SPRY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ARS Pharmaceuticals Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Ars Pharmaceuticals Inc Azioni (SPRY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):